Farmak has supplemented the Moleskin® dermatological line. Domestic pharmaceutical manufacturer specialists have developed and brought to market a combination drug product Moleskin C in the form of an ointment used to treat chronic skin diseases.
Moleskin C is a combination drug product containing an anti-inflammatory, anti-pruritic and anti-allergic component mometasone furoate and exfoliating component salicylic acid.
Moleskin C is used to treat chronic dermatological diseases such as psoriasis, eczema, dermatitis etc., which are accompanied by coarse skin and impaired keratinization.
Olena Alexeeva, Marketing Consultant, Farmak Marketing Department for Prescription Drug Products: “Mometasone furoate which is a component of Moleskin C is the safest topical hormonal drug and does not cause local or systemic side effects even during prolonged use. Mometasone quickly relieves major symptoms of dermatitis (itching, inflammation and redness). It is the only topical hormonal agent, the evidence base of which includes the research conducted in Germany among 22,831 patients involving 5,500 physicians. The study recorded no side effects with maximum anti-pruritic and anti-inflammatory efficacy.
Salicylic acid, a component of the new formula, shows antiseptic and anti-inflammatory action, softens thickened exfoliating layers and enhances the action of mometasone by promoting its absorption.
Thus, the combination of mometasone and salicylic acid in Moleskin C can both enhance the anti-inflammatory and anti-pruritic action and quickly return the skins’ healthy aesthetic look which is so important for patients with chronic dermatological diseases.
It should be noted that Moleskin C was investigated in clinical trials at the Ivano-Frankivsk National Medical University which proved its full therapeutic equivalence with the original drug product, containing mometasone furoate and salicylic acid.”
The Memorandum is aimed at developing the mutual cooperation in the implementation of the state programs of the Republic of Uzbekistan for the further development of the national pharmaceutical industry. “We know the Uzbek market well and we are committed to develop cooperation. Farmak has been present in Uzbekistan since 2004. The residents of this [&hellip...
The money will be spent to purchase ventilators, coronavirus rapid tests, protective clothing, masks and disinfectants for hospitals. “In these hard times for the world and the country, business has to become a solid foundation for the state and make every effort to prevent the novel coronavirus 2019-nCoV (COVID-19). Thousands of companies throughout the wor...
Farmak searches for engaging startups in the innovative medical technology market in cooperation with Sector X. “Why are we here? To find new business development points in P4 (predictive, preventive, personalized and participatory) medicine. Admittedly, the corporate sector may effectively operate a customized business model, but it is cumbersome enough to ...